Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
6
×
boston top stories
deals
6
×
life sciences
national blog main
san francisco blog main
clinical trials
national top stories
new york blog main
new york top stories
san francisco top stories
startups
boston
fda
investing
cancer immunotherapy
gene editing
ipo
national
san diego blog main
san diego top stories
vc
480 biomedical
abbvie
acetylon pharmaceuticals
acute myeloid leukemia
allergan
alx oncology
alzheimer's disease
ambys medicines
american society of clinical oncology (asco)
anti-inflammatory drugs
arcturus therapeutics
arsenal medical
autoimmune diseases
avrobio
azacitidine
berkeley lights
beta-thalassemia
What
biotech
6
×
new
medicines
research
days
developing
ipo
raised
startup
therapeutics
today
abbvie
ahead
aiming
aims
alliance
ambien
ambys
american
annual
approach
arrival
asco
attendees
attention
based
big
called
camp’s
cancer
cash
chicago
city
clinical
combinations
community’s
companies
company
control
deadly
Language
unset
Current search:
deals
×
biotech
×
" boston blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More